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Summary The effect of 17 P-oestradiol on a "receptor positive" and on a "receptor negative" human breast
carcinoma grown in nude mice was studied. Experimental growth data were used to determine the effect on
tumour growth. Flow cytometric DNA analysis (FCM) performed on tumour tissue obtained by sequential
fine-needle aspirations was used to estimate the effect on the cell cycle. In the receptor-positive breast
carcinoma, oestradiol induced complete tumour regression and characteristic cell cycle changes. In the
receptor-negative breast carcinoma, no changes in tumour growth and cell cycle distribution could be
demonstrated following the treatment.
The results indicate that the oestradiol-induced cell kill could be explained to some extent by the induction
of polyploid cells, which eventually die. Since the cell cycle changes monitored by FCM in the receptor-
positive breast carcinoma appeared prior to any reduction in the tumour size, the results suggest that FCM
may prove a valuable method in the early detection of tumour response to hormone treatment in human
breast cancer.
The basic mechanism of action of hormone therapy
leading to tumour regression is not clearly
understood. It has been shown that hormones
induce cell kinetic changes in hormone sensitive
tumour cells in vitro (Lippmann et al., 1976;
Weichselbaum et al., 1978) and in vivo
(Nordenskj6ld et al., 1976; Dao et al., 1982), but
whether the treatment acts by a suppression of cell
proliferation or by a cytotoxic action resulting in
cell death remains to be established.
Flow cytometric DNA analysis (FCM) has been
introduced as a method for obtaining rapid
information on cell cycle changes induced by
radiotherapy and chemotherapy in experimental
tumours (Spang-Thomsen et al., 1982; Gohde et al.,
1975), and by chemotherapy in clinical tumours
(Vindel0v et al., 1982a).
The present paper describes the effect of 17f-
oestradiol on an oestrogen and progesterone
receptor-positive and on an oestrogen and
progesterone receptor-negative human breast
carcinoma grown in castrated male nude mice.
Experimental growth data were used to determine
on the effect on tumour growth, and FCM analysis
of tumour tissue obtained by sequential fine needle
aspirations was used to estimate the effect on the
cell cycle. In the receptor-positive breast carcinoma,
oestradiol induced complete tumour regression and
characteristic cell cycle changes. In the receptor-
negative breast carcinoma, the treatment had no
effect on growth or on cell cycle kinetics.
The results suggest a relationship between the cell
cycle pertubations and the cell killing effect of
oestradiol, and thus indicate that FCM may be
used in the early assessment of the clinical response
to oestradiol treatment.
Materials and methods
Tumours
The two human breast carcinomas studied were
kindly supplied by Dr. G.B. Bastert, Klinikum der
Johann Wolfgang Goethe Universitat, Frankfurt
am Main. One tumour (T61) was derived from a
mastectomy on a 54-year-old postmenopausal
woman; the other carcinoma (T60) was obtained
from a mastectomy on a 31-year-old
premenopausal woman. Both patients were
untreated prior to the surgery.
The tumours were serially grown in nude mice
and were transferred to our laboratory in the 11th
and 24th transplant generations of the post
menopausal and premenopausal carcinomas,
respectively. The present investigations were
performed on tumours from passage 17 (T61) and
34 (T60) in nude mice.
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Histology:
Histological sections from untreated mouse-grown
tumours were stained with H and E and by the van
Gieson method. The T61 tumour was composed of
well-delimited solid islands of a moderately
differentiated carcinoma exhibiting ductal features
(ductal carcinoma of the moderately differentiated
type). The T60 tumour was composed of rather
low-differentiated solid tumour islands (unclassified
undifferentiated carcinoma).
Animals:
Specific pathogen-free (SPF) male NC/KH nude
mice (Kommunehospitalet, Copenhagen) were kept
under sterile conditions in a laminar flow clean
bench. The room temperature was 25+2°C, the
relative humidity was 55% +5%. Sterile food and
water were given ad libitum.
Transplantation:
The tumours were grown in male mice, castrated at
least one week before transplantation. A tissue
block of - 2mm was inoculated s.c. in each flank
of the mice. The procedure was performed under
general anaesthesia with propanidid (Epontholg).
Tumours were excluded if the animals died before
the end of the experimental period, which was at
least 28 days following the treatment. In addition,
tumours demonstrating growth by less than 6
growth recordings prior to the day of treatment
were excluded (Spang-Thomsen et al., 1981).
Hormone treatment:
The mice were treated with 1 mg 17f,-oestradiol
(0.1 ml Progynon depot®' 10mgml -1, Schering AG,
Berlin), as a single i.m. dose into the thigh. The
tumours investigated comprised 20 treated and 12
untreated control tumours of T61, and 18 treated
and 18 untreated controls of T60. The treatment
was given at day 44 after transplantation in mice
bearing T61 and at day 34 in mice bearing T60.
In a separate experiment, the serum oestradiol
level in treated mice was determined by
radioimmunoassay (Emment et al., 1972). The
assay was performed daily during the first 8 days
after treatment. The serum concentrations of
oestradiol varied from 1.36 x 10-7M at Day 1
(peak concentration) to 0.24 x 10-7M at Day 8.
Receptor assay:
Tumour samples for oestradiol and progesterone
receptor assay were frozen immediately after
excision and stored at -80°C. The receptor level
determinations were conducted using the dextran-
coated charcoal assay method (E.O.R.T.C., Breast
Co-operative Group, 1980). The receptor content
and the dissociation constants were determined
according to the method of Scatchard (1949). A
positive oestradiol or progesterone receptor assay
was taken to be . 10fmolmg-1 ofcytosol protein. In
the present investigation, 4 untreated T61 and 2
untreated T60 tumours were analyzed for receptor
content.
Flow cytometric DNA analysis:
The samples for FCM were obtained by sequential
fine-needle aspirations. The aspiration procedure,
storage of aspirates, and staining by propidium-
iodide were performed as previously described
(Vindel0v et al., 1977; 1982b; 1982c). The flow
cytometer used was a FACS III cell sorter (Becton
Dickinson, Sunnyvale, CA.). The cellular DNA
content was expressed as the DNA index (Barlogie
et al., 1976) determined by the use of two internal
standards (Vindel0v et al., 1982d). The percentage
of cells in the cycle phases was determined by a
statistical analysis of the DNA distribution
(Christensen et al., 1978).
Growth data:
Tumour measurements were used to construct
rectilinear growth curves according to a
transformed Gompertz function (Spang-Thomsen et
al., 1980). On the basis of this function, two
regression lines were constructed for all growth
curves, one before and one after treatment. Six
experimental points were used for the determination
of each of these lines. Normalized growth curves
for each of the two breast carcinomas were
constructed by correcting all growth data with the
difference between the common mean tumour size
at the time of treatment and the mean tumour size
at the time of treatment in the individual treatment
groups (Spang-Thomsen et al., 1981).
Results
Figures 1 and 2 show the mean transformed
Gompertz growth curves of the two breast
carcinomas. The solid lines represent the calculated
mean regression lines. Figure 1 indicates that
oestradiol induced a substantial change in the
growth of T61 tumours, resulting in the complete
regression of all tumours. The tumour shrinkage
commenced - 12 days after treatment. Some
tumours were observed for 75 days after treatment,
and no regrowth was observed.
In the T60 tumour (Figure 2), the growth was
unaffected by hormone treatment. The difference
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seen to the right of the G2 +M peak in the
histograms (Figure 3 b and c).
No significant differences in the DNA
distribution between treated and control tumours
were demonstrated in the T60 tumour (Figure 3 d-f,
and Figure 4 c and d).
Representative values of growth rate, receptor
content, DNA index, and DNA distribution of
untreated tumours are summarized in the Table.
The values are in accordance with results obtained
20 30 40 50 60 70 in previous passages in nude mice.
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Figure 1 Mean transformed Gompertz growth curves
of a receptor-positive human breast carcinoma (T61)
transplanted to nude mice at day 0. Tumours were
treated with 1.0mg 17,B-oestradiol at day 44 (arrow).
The points represent mean values of experimental
growth data of 20 treated (0) and 12 untreated (0)
tumours.
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Figure 2 Mean transformed Gompertz growth curves
of a receptor-negative human breast carcinoma (T60)
transplanted to nude mice at Day 0. Tumours were
treated with 1.0mg 17,B-oestradiol at Day 34 (arrow).
The points represent mean values of experimental
growth data of 18 treated (0) and 18 untreated (0)
tumours.
lines of controls and treated T60 tumours was not
significant (t = 1.32P>0.05).
Representative sequences of DNA distributions
from the two carcinomas are shown in Figure 3,
and the percentage of cells in the cell cycle phases is
plotted in Figure 4 as a function of time after
treatment. It appears that the treatment induced
cell cycle pertubations in tumour T61 from Day 4
after treatment. The changes comprised a decrease
in the fraction of G1 cells and an accumulation of
cells in the S phase of the cell cycle, accompanied
from Day 7 after treatment by an increasing
fraction of polyploid cells. The polyploid cells are
Discussion
In this study, a correlation was demonstrated
between oestradiol responsiveness, as defined by
tumour growth response, and FCM-monitored cell
cycle changes in two human breast carcinomas
grown in nude mice.
The results suggest that the pertubations of the
cell cycle of T61 tumours, especially the
polyploidization of tumour cells, are closely related
to the mechanisms of cell killing by oestradiol. This
interpretation is consistent with the report of Tobey
et al. (1978), who demonstrated that drug-induced
polyploid cells are usually among the first to die
out in a drug-treated population. Furthermore, the
decrease in the G1 fraction and the polyploidization
are in accordance with previous descriptions of
histological changes following oestradiol treatment
of the T61 tumour, showing the disappearance of
mitoses together with the appearance of an
increasing number of tumour giant cells (Bruinner &
Visfeldt, 1982).
The complete tumour regression with no
regrowth or redistribution in the experimental
period indicates that oestradiol treatment has a
cytotoxic effect. However, the experimental period
in this study was chosen arbitrarily: FCM analyses
were performed daily for 21 days after treatment
and growth measurements simultaneously 3 times a
week for 4 weeks. Only a few tumours were
observed for regrowth for 75 days after treatment.
Thus, it cannot be excluded that a longer
observation period for all tumours might have
demonstrated regrowth.
It has been demonstrated in in vitro investigations
of human mammary cancer cells that the inhibitory
effect of oestradiol on growth is associated with a
decrease in the number of cells in the S phase
(Lippman et al., 1976; Weichselbaum et al., 1978).
In the present investigation, the inhibitory effect on
growth in tumour T61 was accompanied by an
increase in the S phase fraction. However, the FCM
results cannot be used to determine the extent to
which the cells accumulated in S have stopped their
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Figure 3 DNA distributions of two human breast carcinomas grown in nude mice. a-c represent DNA
histograms of the receptor-positive T61 breast carcinoma; d-f represent DNA histograms of the receptor-
negative T60 breast carcinoma. The analyses were taken 0 (a and d), 7 (b and e), and 12 (c and 0 days after
treatment. The peaks marked D represent diploid mouse stromal cells, and the C and T peaks are internal
standards used to calculate the DNA index (Vindel0v et al., 1982d). The parts of DNA histograms produced
by G1, S and G2 + M cells are indicated in the figures. Polyploid cells:*FLOW CYTOMETRY AND OESTRADIOL RESPONSIVENESS 645
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Figure 4 DNA cell cycle distribution of two human breast carcinomas grown in nude mice after oestradiol
treatment at Day 0. The percentage of cells in the cell cycle phases and the fraction of polyploid cells is
plotted as a function of time after treatment. a and b represent DNA distributions from untreated and treated
T61 tumours, respectively; c and d represent DNA distributions from treated and untreated T60 tumours,
respectively.
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Table I Growth characteristics of two human breast carcinomas grown in nude mice
Growth ratea Oestradiol Receptor Progesterone Receptor
x iO- Conc.f Kdg Conc! Kdg DNA-Index GI ±s.d.h S+s.d.h G2+M+s.d.h
T60 16.4b 11.2c <10 <10 1.52 73.10+5.68 17.42+3.88 9.46+2.98
T61 14.7d 8.4e 88 0.8 78 3.9 1.37 54.96+6.49 36.41 +6.36 8.63+0.96
(a) The growth rate= the slope of the mean transformed Gompertz curves, based on growth recordings from days 20-34
(b) and 34-48 (c) after transplantation of T60, and days 28-44 (d) and 56-70 (e) after transplantation of T61.
(f) Receptor concentration (fmolmg-' cytosol protein).
(g) Binding constant ( x 10- 0M).
(h) Mean percentage of cells in the cell cycle phases+s.d.
DNA synthesis, and thus are proliferatively dead.
This aspect is currently under investigation.
It is of particular interest that the effect of
oestradiol was associated with an S phase
accumulation followed by a subsequent formation
of polyploid cells, since the effect of tamoxifen, a
non-sterodial anti-oestrogen, has been demonstrated
to be associated with an accumulation of cells in
the G1 phase of the cell cycle (Sutherland & Taylor,
1981). Thus, these different observations on cell
kinetics favour the hypothesis that oestradiol and
tamoxifen have different sites of action (Butler et al.,
1981).
An evaluation of the response to endocrine
therapy in patients with breast cancer is at present
based on treatment-induced changes in tumour size,
the only parameter available. This study has shown
that oestradiol induced characteristic cell cycle
changes in a hormone responsive tumour but not in
a hormone unresponsive tumour, and that the
changes could be monitored by FCM prior to the
reduction in tumour size. Since the FCM method is
simple and results are available a few hours after
the biopsy, the present results indicate that the
FCM method may prove applicable for an
objective, early, and rapid evaluation of tumour
response to hormone treatment in human breast
cancer patients with tumours accessible for fine-
needle aspiration.
Human solid tumours may be heterogeneous and
constitute cell populations with varying sensitivity
to anti-cancer treatment (Tropez et al., 1979;
Engelholm et al., 1982). Furthermore, heterogeneity
has been demonstrated among metastases
originating from the same primary tumour
(Webster et al., 1978; Brennan et al., 1979). Thus
heterogeneity may limit the clinical use of FCM in
the evaluation of response.
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